厄贝沙坦治疗早期糖尿病肾病的临床研究

目的评价厄贝沙坦用于治疗早期糖尿病肾病(diabetic nephropathy,DN)患者的疗效。方法 80例DN患者,分成观察组和对照组。对照组单用辛伐他汀治疗。观察组厄贝沙坦+辛伐他汀治疗。结果治疗后:观察组24hu-MA、TG、TC、LDL-C、收缩压和舒张压等均显著性降低(P0.001或P0.01);对照组24hu-MA、TG、TC均显著性降低(P0.001或P0.01)。两组组间比较:观察组24hu-MA、TG、TC、LDL-C、收缩压和舒张压均明显低于对照组,具有显著性差异(P0.001或P0.05)。两组均未见明显的不良反应。结论 "厄贝沙坦+辛伐他汀"治疗早期DN患者疗效佳,而且也比较安全,建议临床推广应用。

Clinical Research about Irbesartan in the Treatment of Early Diabetic Nephropathy

Objective Evaluation efficacy about Irbesartan in the treatment of early diabetic nephropathy. Methods 80 patients with DN were divided into observation group and control group. Control group： single treatment with simvastatin. Observer Group： Irbesartan ＋ Simvastatin. Results After treatment： observation group 24h u-MA, TG, TC, LDL-C, systolic and diastolic blood pressure, were significantly lower （P〈0.001 or 0.01 ）; control group 24h u-MA, TG, TC were significantly lower （P〈0.001 or 0.01 ）. Between the two groups： the observation group 24h u-MA, TG, TC, LDL-C, systolic and diastolic blood pressure were significantly lower than the control group, with significant difference （P〈O.001 or 0.05, Table 1 ）. Both groups were no obvious adverse reactions. Conclusion Irbesartan ＋ Simvastatin in the treatment of early diabetic nephropathy, efficacy reliable, safe, worthy of clinical application and popularization.